Iran war threatens a global recession, Finland’s Stubb warns – POLITICO
“Diplomacy is rarely a transaction,” he said. “I mean, interest can be transactional, but even then, you should…
Eli Lilly’s obesity drug retatrutide clears late-stage diabetes trial
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike…
J&J wins approval for first-of-its-kind psoriasis pill
Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing…
Vertex says drug reduced marker of kidney disease in late-stage trial
Vertex said Monday that a drug it secured as part of a $4.9 billion acquisition successfully reduced by…
5 lessons from Vinay Prasad’s turbulent tenure at the FDA
Food and Drug Administration official Vinay Prasad self-destructed last week. The FDA announced Friday evening that he would…
TrumpRx: High expectations, but limited impact a month after launch
WASHINGTON — President Trump heralded his signature drug discount platform, TrumpRx, as “one of the most transformative health…
Key study of Grail’s cancer detection test fails in setback for company
Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT…
FDA reverses course, agrees to review Moderna’s flu vaccine
WASHINGTON — The Food and Drug Administration reversed course and told Moderna it would review its application for…
Moderna’s president weighs in on FDA’s decision not to review its flu vaccine
Food and Drug Administration officials told Moderna in August that they would review its application for a new…
Prasad overruled FDA staff to reject Moderna flu vaccine application
WASHINGTON — Top Food and Drug Administration official Vinay Prasad overruled the agency’s reviewers when he refused to accept…
FDA refuses to review Moderna’s flu vaccine application
Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her…
FDA rejects Regenxbio’s MPS II rare-disease gene therapy
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…